Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marianne Berwick is active.

Publication


Featured researches published by Marianne Berwick.


Cancer | 1996

Predicting five‐year outcome for patients with cutaneous melanoma in a population‐based study

Raymond L. Barnhill; Judith A. Fine; George C. Roush; Marianne Berwick

In numerous studies tumor thickness has been shown to be the most important prognostic factor for patients with localized cutaneous melanoma. However, to our knowledge there are no population‐based studies analyzing the prognosis of patients living in the United States with cutaneous melanoma.


Trends in Cell Biology | 2001

Double-strand breaks and tumorigenesis

Andrew J. Pierce; Jeremy M. Stark; Felipe D. Araujo; Mary Ellen Moynahan; Marianne Berwick; Maria Jasin

The establishment of connections between biochemical defects and clinical disease is a major goal of modern molecular genetics. In this review, we examine the current literature that relates defects in the two major DNA double-strand-break repair pathways--homologous recombination and nonhomologous end-joining--with the development of human tumors. Although definitive proof has yet to be obtained, the current literature is highly suggestive of such a link.


Cancer | 2000

Patterns of detection in patients with cutaneous melanoma

Mary S. Brady; Susan A. Oliveria; Paul J. Christos; Marianne Berwick; Daniel G. Coit; Jared Katz; Allan C. Halpern

Despite the importance of early detection in preventing mortality from melanoma, little is known regarding how patients with the disease come to diagnosis.


Cancer Research | 2004

The ADPRT V762A Genetic Variant Contributes to Prostate Cancer Susceptibility and Deficient Enzyme Function

Kristin L. Lockett; M. Craig Hall; Jianfeng Xu; S. Lilly Zheng; Marianne Berwick; Shu-Chun Chuang; Peter E. Clark; Scott D. Cramer; Kurt Lohman; Jennifer J. Hu

The ADP-ribosyltransferase (ADPRT) gene encodes a zinc-finger DNA-binding protein, poly(ADP-ribose) polymerase-1 (PARP-1), that modifies various nuclear proteins by poly(ADP-ribosyl)ation and functions as a key enzyme in the base excision repair pathway. We have conducted two studies to test whether an amino acid substitution variant, ADPRT V762A (T2444C), is associated with prostate cancer (CaP) risk and decreased enzyme function. The first study used genomic DNA samples from an ongoing, clinic-based case-control study (488 cases and 524 controls) to show that a higher percentage of the CaP cases carried the ADPRT 762 AA genotype than controls (4% versus 2%). In Caucasians, the AA genotype was significantly associated with increased CaP risk [odds ratio (OR), 2.65; 95% confidence interval (CI), 1.08–6.49], and the VA genotype was associated with a slight but not significantly increased CaP risk (OR, 1.18; 95% CI, 0.85–1.64) using VV as the referent group after adjustment for age, benign prostatic hyperplasia, and family history. Furthermore, this association was stronger in younger (<65) men (OR, 4.77; 95% CI, 1.01–22.44) than older (≥65) men (OR, 1.78; 95% CI, 0.55–5.82). The second study used freshly isolated peripheral lymphocytes from 354 cancer-free subjects to demonstrate that the ADPRT 762 A allele contributed to significantly lower adenosine diphosphate ribosyl transferase (ADPRT)/PARP-1 activities in response to H2O2 in a gene dosage-dependent manner (P < 0.0001, test for linear trend). The PARP-1 activities (mean ± SD dpm/106 cells) were 18,554 ± 9,070 (n = 257), 14,847 ± 7,082 (n = 86), and 12,155 ± 6,334 (n = 11) for VV, VA, and AA genotypes, respectively. This study is the first to provide evidence that the ADPRT V762A-genetic variant contributes to CaP susceptibility and altered ADPRT/PARP-1 enzyme function in response to oxidative damage.


American Journal of Preventive Medicine | 1999

Thorough skin examination for the early detection of melanoma

Martin A. Weinstock; Rosemarie A. Martin; Patricia Markham Risica; Marianne Berwick; Thomas M. Lasater; William Rakowski; Michael G. Goldstein; Catherine Dubé

BACKGROUNDnMelanoma is a major public health problem for which early detection may reduce mortality. Since melanoma is generally asymptomatic, this requires skin examination. We sought to evaluate the extent to which the general public has their skin examined by themselves, their partners, or health care providers and the frequency of these examinations.nnnMETHODSnRandom-digit-dial survey of adult Rhode Islanders.nnnRESULTSnOnly 9% performed a thorough skin examination (TSE) at least once every few months, although over half of the sample reported conducting skin self-examination deliberately and systematically. Participants were more likely to perform TSE if they were women and if their health care provider had asked them to examine their skin. Most participants reported that their health care provider never or rarely looked at the areas of their skin in which melanoma is most likely to arise.nnnCONCLUSIONSnThe reported frequency of skin self-examination depends critically on the manner of inquiry. TSE by self or a partner is uncommon, and health care providers do not routinely examine the areas of the skin on which melanomas commonly arise.


Cancer Research | 2006

Population-Based Study of Natural Variation in the Melanocortin-1 Receptor Gene and Melanoma

Peter A. Kanetsky; Timothy R. Rebbeck; Amanda J. Hummer; Saarene Panossian; Bruce K. Armstrong; Anne Kricker; Loraine D. Marrett; Robert C. Millikan; Stephen B. Gruber; Hoda Anton Culver; Roberto Zanetti; Richard P. Gallagher; Terence Dwyer; Lynn From; Urvi Mujumdar; Homer Wilcox; Colin B. Begg; Marianne Berwick

Natural variation in the coding region of the melanocortin-1 receptor (MC1R) gene is associated with constitutive pigmentation phenotypes and development of melanoma and nonmelanoma skin cancers. We investigated the effect of MC1R variants on melanoma using a large, international population-based study design with complete determination of all MC1R coding region variants. Direct sequencing was completed for 2,202 subjects with a single primary melanoma (controls) and 1,099 subjects with second or higher-order primary melanomas (cases) from Australia, the United States, Canada, and Italy. We observed 85 different MC1R variants, 10 of which occurred at a frequency >1%. Compared with controls, cases were more likely to carry two previously identified red hair (R) variants [D84E, R151C, R160W, and D294H; odds ratio (OR), 1.6; 95% confidence interval (95% CI), 1.1-2.2]. This effect was similar among individuals carrying one R variant and one r variant (defined as any non-R MC1R variant; OR, 1.6; 95% CI, 1.3-2.2) and among those carrying only one R variant (OR, 1.5; 95% CI, 1.1-1.9). There was no statistically significant association among those carrying only one or two r variants. Effects were similar across geographic regions and categories of pigmentation characteristics or number of moles. Our results confirm that MC1R is a low-penetrance susceptibility locus for melanoma, show that pigmentation characteristics may not modify the relationship of MC1R variants and melanoma risk, and suggest that associations may be smaller than previously reported in part due to the study design.


British Journal of Dermatology | 2010

Increased thickness of pregnancy-associated melanoma.

R.L. Travers; Arthur J. Sober; Marianne Berwick; Martin C. Mihm; R.L. Harnhill; Lyn M. Duncan

Summary The effects of pregnancy on the pathophysiology of melanoma remain unclear. Although a gender‐specific advantage for women vs. men is seen for characteristics such as stage at presentation, site of primary tumour, and survival time, an adverse effect of pregnancy on melanoma development and progression has been reported.


Journal of Cutaneous Pathology | 2005

The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma

Raymond L. Barnhill; Jason Katzen; Alain Spatz; Judith Fine; Marianne Berwick

Background:u2002 Tumor ulceration (TU) is considered the second most important prognostic factor after Breslow thickness for localized cutaneous malignant melanoma (CMM). However, many studies have not included mitotic rate (MR) with TU in these analyses. When both TU and MR are included in the same analysis, MR appears to be the more important than TU and TU loses its significance as an independent prognostic factor.


American Journal of Human Genetics | 2007

Hypomorphic Mutations in the Gene Encoding a Key Fanconi Anemia Protein, FANCD2, Sustain a Significant Group of FA-D2 Patients with Severe Phenotype

Reinhard Kalb; Kornelia Neveling; Holger Hoehn; Hildegard Schneider; Yvonne Linka; Sat Dev Batish; Curtis Hunt; Marianne Berwick; Elsa Callén; Jordi Surrallés; José A. Casado; Juan A. Bueren; Ángeles Dasí; Jean Soulier; Eliane Gluckman; C. Michel Zwaan; Rosalina van Spaendonk; Gerard Pals; Johan P. de Winter; Hans Joenje; Markus Grompe; Arleen D. Auerbach; Helmut Hanenberg; Detlev Schindler

FANCD2 is an evolutionarily conserved Fanconi anemia (FA) gene that plays a key role in DNA double-strand-type damage responses. Using complementation assays and immunoblotting, a consortium of American and European groups assigned 29 patients with FA from 23 families and 4 additional unrelated patients to complementation group FA-D2. This amounts to 3%-6% of FA-affected patients registered in various data sets. Malformations are frequent in FA-D2 patients, and hematological manifestations appear earlier and progress more rapidly when compared with all other patients combined (FA-non-D2) in the International Fanconi Anemia Registry. FANCD2 is flanked by two pseudogenes. Mutation analysis revealed the expected total of 66 mutated alleles, 34 of which result in aberrant splicing patterns. Many mutations are recurrent and have ethnic associations and shared allelic haplotypes. There were no biallelic null mutations; residual FANCD2 protein of both isotypes was observed in all available patient cell lines. These analyses suggest that, unlike the knockout mouse model, total absence of FANCD2 does not exist in FA-D2 patients, because of constraints on viable combinations of FANCD2 mutations. Although hypomorphic mutations arie involved, clinically, these patients have a relatively severe form of FA.


Annals of Epidemiology | 2003

Lung Cancer Risk in White and Black Americans

Steven D. Stellman; Yu Chen; Joshua E. Muscat; Mirjana V. Djordjevic; John P. Richie; Philip Lazarus; Seth Thompson; Nasser K. Altorki; Marianne Berwick; Marc L. Citron; Susan Harlap; Tajinder B. Kaur; Alfred I. Neugut; Sara H. Olson; John M. Travaline; Philip Witorsch; Zuo-Feng Zhang

PURPOSEnTo test whether differences in smoking-related lung cancer risks in blacks and whites can explain why lung cancer incidence is greater in black males than in white males but about equal in black and white females, given that a greater proportion of blacks are smokers, but smoke far fewer cigarettes per day than do whites.nnnMETHODSnA hospital-based case-control study was conducted between 1984 and 1998 that included interviews with 1,710 white male and 1,321 white female cases of histologically confirmed lung cancer, 254 black male and 163 black female cases, and 8,151 controls. Relative risks were estimated via odds ratios using logistic regression, adjusted for age, education, and body mass index.nnnRESULTSnWe confirmed prior reports that smoking prevalence is higher but overall dosage is lower among blacks. Overall ORs were similar for blacks and whites, except among the heaviest smoking males (21+ cigarettes per day or 37.5 pack-years), in whom ORs for blacks were considerably greater than for whites. Long-term benefits of cessation were similar for white and black ex-smokers. Smokers of menthol flavored cigarettes were at no greater risk for lung cancer than were smokers of unflavored brands.nnnCONCLUSIONSnLung cancer risks were similar for whites and blacks with similar smoking habits, except possibly for blacks who were very heavy smokers; this sub-group is unusual in the general population of African American smokers. Explanations of racial disparities in lung cancer risk may need to account for modifying factors including type of cigarette (yield, mentholation), diet, occupation, and host factors such as ability to metabolize mainstream smoke carcinogens.

Collaboration


Dive into the Marianne Berwick's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Allan C. Halpern

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Colin B. Begg

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Susan A. Oliveria

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Daniel G. Coit

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Irene Orlow

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mary S. Brady

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Nancy E. Thomas

University of North Carolina at Chapel Hill

View shared research outputs
Researchain Logo
Decentralizing Knowledge